bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) and Oscar Health (NYSE:OSCR – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.
Risk & Volatility
bioAffinity Technologies has a beta of -1.03, suggesting that its stock price is 203% less volatile than the S&P 500. Comparatively, Oscar Health has a beta of 2.56, suggesting that its stock price is 156% more volatile than the S&P 500.
Insider & Institutional Ownership
1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 75.7% of Oscar Health shares are held by institutional investors. 2.4% of bioAffinity Technologies shares are held by insiders. Comparatively, 22.6% of Oscar Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current recommendations for bioAffinity Technologies and Oscar Health, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| bioAffinity Technologies | 1 | 0 | 0 | 0 | 1.00 |
| Oscar Health | 1 | 7 | 4 | 1 | 2.38 |
Oscar Health has a consensus target price of $34.60, indicating a potential upside of 12.55%. Given Oscar Health’s stronger consensus rating and higher probable upside, analysts clearly believe Oscar Health is more favorable than bioAffinity Technologies.
Valuation and Earnings
This table compares bioAffinity Technologies and Oscar Health”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| bioAffinity Technologies | $6.16 million | 0.26 | -$14.91 million | ($44.27) | -0.06 |
| Oscar Health | $17.47 billion | 0.54 | -$443.15 million | $2.42 | 12.70 |
bioAffinity Technologies has higher earnings, but lower revenue than Oscar Health. bioAffinity Technologies is trading at a lower price-to-earnings ratio than Oscar Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares bioAffinity Technologies and Oscar Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| bioAffinity Technologies | -278.90% | -278.67% | -154.52% |
| Oscar Health | 4.90% | 49.39% | 9.29% |
Summary
Oscar Health beats bioAffinity Technologies on 14 of the 15 factors compared between the two stocks.
About bioAffinity Technologies
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
About Oscar Health
Oscar Health, Inc. operates as a health insurance in the United States. The company offers health plans in individual and small group markets, as well as +Oscar, a technology driven platform that help providers and payors directly enable their shift to value-based care. It also provides reinsurance products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
